10 Best Small-Cap Stocks to Buy Before They Explode

3. Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Market Capitalization: $1.749 Billion

Analyst Upside Potential: 67.13%

Number of Hedge Fund Holders: 33

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) is a biopharmaceutical company that specializes in the development of transformative therapies for rare genetic diseases, with a strong focus on hemolytic anemias and other genetically defined conditions. It is known for its PYRUKYND, which is a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, approved as the first disease-modifying therapy for hemolytic anemia.

During the fiscal fourth quarter of 2024, Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) reported that it is leveraging its flagship product, PYRUKYND, to target additional rare diseases. It anticipates regulatory approval for thalassemia in September 2025 and a potential launch for sickle cell disease in 2026. It is also enhancing its pipeline and is progressing its early and mid-stage pipeline, for Tebapivat and AG-236.

In 2024, Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) reported a total revenue of $542.3 million, driven by the success of PYRUKYND and other therapies. The fiscal 2025 is expected to be a transformative year for the company as it expects FDA decisions on PYRUKYND for thalassemia, and phase III results for mitapivat in sickle cell disease. Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) is one of the best small cap stocks to buy before they explode.